NICE knocks-back Janssen’s Imbruvica in mantle cell lymphoma
But recommends it for the rare cancer Waldenstrom’s macroglobulinaemia
Read MoreBut recommends it for the rare cancer Waldenstrom’s macroglobulinaemia
Read MoreOpens new Bangalore office to bolster its global offering
Read MoreWill be better placed to compete head on with ViiV’s rival integrase inhibitor Tivicay
Read MoreMeets its Phase III targets but concerns remain over its side effects profile
Read MoreBelgium’s Ogeda is now a wholly-owned subsidiary of the Japanese pharma firm
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479